Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:FGEN NASDAQ:HUMA NASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.27-6.3%$1.90$0.78▼$4.98$171.71M1.871.43 million shs658,025 shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsHUMAHumacyte$0.66-1.3%$0.96$0.55▼$2.84$147.58M2.5216.66 million shs3.02 million shsTLSATiziana Life Sciences$1.02-5.1%$1.27$0.99▼$2.60$136.17M0.46203,751 shs212,494 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-6.64%+2.10%+16.59%-69.18%-58.52%FGENFibroGen0.00%0.00%0.00%0.00%+27.71%HUMAHumacyte-1.28%-5.06%-29.01%-0.42%-71.84%TLSATiziana Life Sciences-5.14%-23.68%-12.50%-17.48%-34.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.27-6.3%$1.90$0.78▼$4.98$171.71M1.871.43 million shs658,025 shsFGENFibroGen$9.77+8.3%$9.21$4.85▼$12.60$39.57M0.7740,794 shs31,125 shsHUMAHumacyte$0.66-1.3%$0.96$0.55▼$2.84$147.58M2.5216.66 million shs3.02 million shsTLSATiziana Life Sciences$1.02-5.1%$1.27$0.99▼$2.60$136.17M0.46203,751 shs212,494 shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics-6.64%+2.10%+16.59%-69.18%-58.52%FGENFibroGen0.00%0.00%0.00%0.00%+27.71%HUMAHumacyte-1.28%-5.06%-29.01%-0.42%-71.84%TLSATiziana Life Sciences-5.14%-23.68%-12.50%-17.48%-34.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 2.33Hold$6.25394.07% UpsideFGENFibroGen 2.00Hold$43.00340.12% UpsideHUMAHumacyte 2.75Moderate Buy$6.25852.45% UpsideTLSATiziana Life Sciences 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest FGEN, TLSA, ADCT, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026ADCTADC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026TLSATiziana Life Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/8/2026HUMAHumacyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/17/2026HUMAHumacyte TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.256/16/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/11/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.006/8/2026ADCTADC Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral6/8/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/4/2026ADCTADC Therapeutics StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.006/4/2026ADCTADC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026ADCTADC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$6.00 ➝ $2.00(Data available from 7/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$81.36M1.98N/AN/A($1.50) per share-0.84FGENFibroGen$29.62M1.34N/AN/A($50.89) per share-0.19HUMAHumacyte$2.04M71.42N/AN/A$0.02 per share32.81TLSATiziana Life SciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$142.62M-$1.05N/AN/AN/A-173.02%N/A-44.70%8/11/2026 (Estimated)FGENFibroGen-$47.58M$53.480.18N/AN/A2,598.55%N/A-26.27%N/AHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)TLSATiziana Life Sciences-$18.43MN/AN/AN/AN/AN/AN/AN/A9/18/2026 (Estimated)Latest FGEN, TLSA, ADCT, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ADCTADC Therapeutics-$0.19N/AN/AN/A$18.89 millionN/A8/10/2026Q2 2026HUMAHumacyte-$0.10N/AN/AN/A$1.12 millionN/A5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 million5/4/2026Q1 2026ADCTADC Therapeutics-$0.19-$0.21-$0.02-$0.21$19.99 million$20.85 million5/1/2026Q4 2025TLSATiziana Life SciencesN/A-$0.2750N/A-$0.2750N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.094.02FGENFibroGenN/A3.713.60HUMAHumacyte5.463.933.32TLSATiziana Life SciencesN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%FGENFibroGen72.71%HUMAHumacyte44.71%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%FGENFibroGen3.07%HUMAHumacyte3.10%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310127.19 million120.32 millionOptionableFGENFibroGen5704.05 million3.92 millionOptionableHUMAHumacyte150222.02 million215.14 millionOptionableTLSATiziana Life Sciences8127.26 million76.58 millionOptionableFGEN, TLSA, ADCT, and HUMA HeadlinesRecent News About These CompaniesTiziana Life Sciences (NASDAQ:TLSA) Rating Increased to Hold at Zacks ResearchJuly 16, 2026 | marketbeat.comTiziana Life Sciences (NASDAQ:TLSA) Shares Up 8.1% - What's Next?July 13, 2026 | marketbeat.comTiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest ReportJuly 13, 2026 | benzinga.comTiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trialJune 25, 2026 | proactiveinvestors.comTiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS TrialJune 25, 2026 | globenewswire.comWhy Tiziana Life Sciences Is Back on the Small-Cap Radar?June 19, 2026 | kalkinemedia.comKTiziana Life Sciences Announces Purchase of Shares by Executive ChairmanJune 15, 2026 | globenewswire.comTiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 29, 2026 | finanznachrichten.deTiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New YorkMay 28, 2026 | globenewswire.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMIMay 22, 2026 | proactiveinvestors.comTiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment UpdateMay 21, 2026 | finance.yahoo.comTiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trialMay 21, 2026 | proactiveinvestors.comTiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis TrialMay 21, 2026 | globenewswire.comTiziana Life Sciences price target boosted on foralumab updateMay 19, 2026 | proactiveinvestors.comTiziana says updated data for multiple sclerosis therapy shows long-term safetyMay 19, 2026 | seekingalpha.comTiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MSMay 19, 2026 | proactiveinvestors.comTiziana Life Sciences Ltd.: Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | finanznachrichten.deTiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple SclerosisMay 19, 2026 | globenewswire.comTiziana Brain Trial Draws Fresh Nasdaq Index AttentionMay 16, 2026 | kalkinemedia.comKTiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trialMay 14, 2026 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFGEN, TLSA, ADCT, and HUMA Company DescriptionsADC Therapeutics NYSE:ADCT$1.26 -0.09 (-6.30%) Closing price 07/20/2026 03:59 PM EasternExtended Trading$1.26 0.00 (-0.40%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.FibroGen NASDAQ:FGENFibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Humacyte NASDAQ:HUMA$0.66 -0.01 (-1.28%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$0.65 0.00 (-0.34%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Tiziana Life Sciences NASDAQ:TLSA$1.01 -0.06 (-5.14%) Closing price 07/20/2026 04:00 PM EasternExtended Trading$1.00 -0.01 (-1.48%) As of 07/20/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? AI Data Centers Need Power, and These 2 Industrials Are Cashing In 5 Stocks Quietly Trading Near All-Time Highs While Everyone Watches the AI Drama Meta Platforms Turns AI Power Scarcity Into a $10 Billion Cloud Bet Why Gold Miners Could Be the Market's Biggest Comeback Story A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Amazon’s AI Spending Is About to Face Its Most Important AWS Test Yet Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
